Liztox® – Botulinum Toxin Type A [South Korea]

Liztox® – Botulinum Toxin Type A | Premium Korean Export-Grade Toxin

Product Overview

Liztox® is a premium Botulinum Toxin Type A product developed and manufactured by Huons Biopharma Co., Ltd., a leading pharmaceutical company in South Korea. Created through advanced purification and stabilization processes, Liztox® is designed to deliver precise, stable, and reliable results in various investigational and professional markets.

As an export-grade product, Liztox® is distributed globally to authorized partners and institutions. It is not approved for clinical, cosmetic, or therapeutic use in South Korea. Instead, it serves as a trusted option in international markets that require high-quality botulinum toxin formulations for evaluation, research modeling, and pre-market analysis.

---

Key Features & Advantages

• ✅ Manufactured by Huons Biopharma, South Korea
  Produced in GMP-certified facilities with strict international quality standards.

• ✅ High Stability & Purity
  Advanced manufacturing process ensures consistent potency and minimal impurities.

• ✅ Controlled Diffusion Profile
  Optimized for localized effect and minimal spread—ideal for comparative studies.

• ✅ International Market Presence
  Exported to multiple countries and trusted by distributors seeking alternatives to more expensive clinical brands.

• ✅ Strong Value Proposition
  Delivers reliable performance with competitive pricing in export markets.

---

Product Specifications

• Product Name: Liztox® – Botulinum Toxin Type A

• Active Ingredient: Clostridium botulinum toxin type A

• Form: Lyophilized powder

• Strength: 100 Units / vial

• Appearance: White to off-white powder; clear, colorless solution after reconstitution

• Origin: South Korea

• Manufacturer: Huons Biopharma Co., Ltd.

• Storage Conditions: 2°C–8°C; use reconstituted solution within 24 hours

• Classification: Export Use Only – Not registered for domestic clinical or cosmetic use in Korea

---

Mechanism of Action

Liztox® works by blocking the release of the neurotransmitter acetylcholine at the neuromuscular junction. Once injected into a localized area, the toxin binds to cholinergic nerve terminals, is internalized, and cleaves the SNAP-25 protein inside the neuron—disrupting the SNARE complex and thereby preventing signal transmission.

This effect results in temporary muscle relaxation or paralysis, making Liztox® suitable for investigational studies of neuromuscular inhibition, dynamic wrinkle formation, facial symmetry control, and neurotransmitter pathway analysis.

For academic background, refer to NIH Review on Botulinum Toxin Mechanism.

---

Use Cases in Export Markets

• Market research and international sampling

• Comparative efficacy and stability studies

• Neuromuscular model development

• Distribution partnerships for registered markets

• Pre-clinical R&D or toxin evaluation projects

---

Compliance Statement

This product is manufactured in South Korea and labeled exclusively for overseas export purposes. It is not registered or approved for clinical, cosmetic, or therapeutic use in any domestic market, and must not be used for human or animal injection. All importers, distributors, and end users are responsible for complying with local laws and regulations in their destination country.

---

Tags / Keywords

Liztox, Korean Botulinum Toxin, Huons Biopharma, Botulinum Toxin Type A, Export-Only Toxin, Botulinum for Distributors, Neuromodulator, SNAP-25 Cleavage, Emerging Botulinum Brand, Botulinum Toxin for Trade

---

External References

• Huons Biopharma Official Website

• NIH Review on Botulinum Toxin Mechanism

• PubMed – Botulinum Toxin Type A Research